Patients and Caregivers Now Have Option for Treating Alzheimer’s-Related Agitation

Washington, DC (May 11, 2023) – Alzheimer’s patients, caregivers, and advocates are applauding the decision by the Food and Drug Administration (FDA) to approve the use of a medication to treat Alzheimer’s-related agitation. The decision makes Rexulti the first drug to be approved for this indication. Russ Paulsen, chief operating officer at UsAgainstAlzheimer’s, released the following statement in response:

“Alzheimer’s disease isn’t just about forgetting things. It impacts a person’s ability to remain independent, to feel safe in their own home, and to handle change or other new stimuli. For many people with Alzheimer’s, restlessness, anxiety, and even aggression are common and disruptive symptoms of the disease. The FDA’s approval of Rexulti to combat Alzheimer’s-related agitation gives patients, caregivers, and their doctors an option, and it serves as yet another example of the important progress being made in fighting this deadly disease.”

About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and access to treatments – all regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.